These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23876164)

  • 41. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system.
    McFarland LV; Clarridge JE; Beneda HW; Raugi GJ
    Clin Infect Dis; 2007 Nov; 45(9):1141-51. PubMed ID: 17918075
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea.
    Choi SY; Lim HA; Yim HW; Park YH
    PLoS One; 2018; 13(4):e0195563. PubMed ID: 29649310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?
    Wang M; Fitzgerald JM; Richardson K; Marra CA; Cook VJ; Hajek J; Elwood RK; Bowie WR; Marra F
    Int J Tuberc Lung Dis; 2011 Aug; 15(8):1062-8. PubMed ID: 21740669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Use of Systemic and Topical Fluoroquinolones.
    Jackson MA; Schutze GE;
    Pediatrics; 2016 Nov; 138(5):. PubMed ID: 27940800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    French DD; Margo CE
    Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial use: a risk factor or a protective factor for acquiring campylobacteriosis?
    Koningstein M; Simonsen J; Helms M; Hald T; Mølbak K
    Clin Infect Dis; 2011 Oct; 53(7):644-50. PubMed ID: 21890769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
    Saurenmann RK; Levin AV; Feldman BM; Laxer RM; Schneider R; Silverman ED
    J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes.
    Winterstein AG; Liu W; Xu D; Antonelli PJ
    Otolaryngol Head Neck Surg; 2013 Feb; 148(2):277-83. PubMed ID: 23264116
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative effectiveness of fluoroquinolones and beta-lactams in the complex therapy of patients with chronic pyelonephritis].
    Tverdoĭ VE; Oskolkov SA; Zhmurov VA; Petrova IuA; Oborotova NV
    Urologiia; 2012; (4):8-12. PubMed ID: 23116015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoroquinolones and the risk of serious arrhythmia: a population-based study.
    Lapi F; Wilchesky M; Kezouh A; Benisty JI; Ernst P; Suissa S
    Clin Infect Dis; 2012 Dec; 55(11):1457-65. PubMed ID: 22865870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases.
    Fife D; Zhu V; Voss E; Levy-Clarke G; Ryan P
    Drug Saf; 2014 Mar; 37(3):171-82. PubMed ID: 24526267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of acute kidney injury associated with the use of fluoroquinolones.
    Bird ST; Etminan M; Brophy JM; Hartzema AG; Delaney JA
    CMAJ; 2013 Jul; 185(10):E475-82. PubMed ID: 23734036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials.
    Karamanis EM; Matthaiou DK; Moraitis LI; Falagas ME
    Spine (Phila Pa 1976); 2008 May; 33(10):E297-304. PubMed ID: 18449029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity.
    Patel SS; Saraiya NV; Tessler HH; Goldstein DA
    JAMA Ophthalmol; 2013 Jun; 131(6):752-8. PubMed ID: 23579549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J; Profant M; Kostrica R; Waskin H
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incidence and risk factors for chronic uveitis following cataract surgery.
    Patel C; Kim SJ; Chomsky A; Saboori M
    Ocul Immunol Inflamm; 2013 Apr; 21(2):130-4. PubMed ID: 23697858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral fluoroquinolones and risk of fibromyalgia.
    Ganjizadeh-Zavareh S; Sodhi M; Spangehl T; Carleton B; Etminan M
    Br J Clin Pharmacol; 2019 Jan; 85(1):236-239. PubMed ID: 30216492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.